Treprostinil Injection
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.trepinjection.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Treprostinil Injection
Sandoz Treprostinil Injection is a generic for the brand-name medicine, Remodulin® (treprostinil) Injection, that is used to treat PAH (WHO Group 1)Explore more
Popular SearchesTreprostinil InjectionSandoz IncThe Treprostinil InjectionSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Treprostinil Injection your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Treprostinil Injection has recently received funding, and reach out quickly before it becomes old news!
Treprostinil Injection, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Treprostinil Injection had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Treprostinil Injection
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Treprostinil Injection launches new products
Funding: Get notified immidiatlly once Treprostinil Injection has new funding data
Check out if Treprostinil Injection is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Treprostinil Injection recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Treprostinil Injection
Compare insights from companies similar to Treprostinil Injection, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Treprostinil Injection
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Treprostinil Injection is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Treprostinil Injection is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Treprostinil Injection.
Treprostinil Injection Tech Stack
A closer look at the technologies used by Treprostinil Injection
Treprostinil Injection News & Media
Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
MORRISVILLE, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the full year ended December 31, 2025. The company will also host a webcast at 8:30 a.m. ET on March 5, 2026, to discuss its financial results and provide a corporate update.Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced its financial results for the third quarter ended September 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on November 3, 2025, to review financial performance and provide a corporate update.Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on August 12, 2025, to review financial performance and provide a corporate update.Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the first quarter ended March 31, 2025. The company will also host a webcast at 8:30 a.m. ET on May 8, 2025 to discuss its financial results and provide a corporate update.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Treprostinil Injection
Sign Up For FreeTo access detailed company insights
Sandoz Treprostinil Injection is a generic for the brand-name medicine, Remodulin® (treprostinil) Injection, that is used to treat PAH (WHO Group 1)... Read More
